How Long Does Cosentyx Stay Active in the Body?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, has a half-life of about 27 days after subcutaneous injection. This means it takes roughly 27 days for half the drug to clear from the bloodstream. Steady-state levels build up over 4-5 doses (about 2-3 months), with full elimination typically occurring 4-6 months after the last dose due to its long half-life.[1][2]
How Long Between Cosentyx Doses?
Standard dosing starts with 300 mg weekly for 5 weeks (subcutaneous injection), then 300 mg every 4 weeks. For some patients (e.g., lower weight or less severe psoriasis), it's 150 mg every 4 weeks. Psoriatic arthritis or ankylosing spondylitis often uses 150-300 mg monthly after loading doses. Doctors adjust based on response and weight.[1][3]
How Long Do Effects Last After Stopping?
Clinical effects can persist 3-6 months post-discontinuation, as the drug suppresses inflammation beyond its detectable levels. Symptom relapse varies: psoriasis plaques may return in 12-16 weeks for many, but some see flares sooner (4-8 weeks). Long-term data shows sustained remission in responders even after pausing.[2][4]
What If I Miss a Cosentyx Dose?
Inject as soon as possible, then resume the regular schedule. If it's near the next dose (within a few days), skip the missed one—don't double up. No evidence of harm from minor delays due to the drug's pharmacokinetics.[1][3]
Factors Affecting Duration in Your Body
- Weight and metabolism: Higher BMI may shorten half-life slightly; liver/kidney issues have minimal impact since it's mostly cleared unchanged via catabolism.
- Antidrug antibodies: Up to 10-20% of patients develop these, potentially reducing efficacy and clearance time.
- Disease severity: Heavier inflammation may lead to faster "functional" clearance despite blood levels.[2][5]
Cosentyx Half-Life Compared to Other Biologics
| Drug | Half-Life | Dosing Frequency |
|------|-----------|------------------|
| Cosentyx (secukinumab) | 27 days | Every 4 weeks |
| Humira (adalimumab) | 14-21 days | Every 1-2 weeks |
| Stelara (ustekinumab) | 21 days | Every 12 weeks |
| Tremfya (guselkumab) | 15-28 days | Every 8 weeks |
Cosentyx's profile allows less frequent dosing than TNF inhibitors like Humira but more often than Stelara.[2][6]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: DrugPatentWatch.com - Secukinumab Pharmacokinetics
[3]: FDA Label for Secukinumab
[4]: Journal of the American Academy of Dermatology - Secukinumab Withdrawal Study (2018)
[5]: Clinical Pharmacology & Therapeutics - Secukinumab ADAs (2020)
[6]: DrugPatentWatch.com - Biologic Half-Life Comparisons